重症COVID-19患者入住ICU时炎症小体相关标志物与预后不相关
这项前瞻性队列研究纳入45例重症COVID-19患者和10例无感染征象的创伤性脑损伤(TBI)患者,入住ICU时采集血浆,检测IL-1a、IL-1β、IL-18、IL-1RA、半乳糖凝集素-1、凋亡相关斑点样蛋白、LDH、铁蛋白和gasdermin D,并用基于抑制剂的免疫沉淀后Western Blot进行无细胞caspase-1血浆检测。COVID-19患者院内死亡率为62%;COVID-19组半乳糖凝集素-1较TBI组低1.8倍(17101.84 pg/mL vs. 30764.20 pg/mL,P=0.007),其他炎症小体相关标志物浓度相似。入住时SOFA评分>9分的高死亡风险患者较低风险患者半乳糖凝集素-1更高(25551.3 pg/mL vs. 16302.7 pg/mL,P=0.014)、IL-1RA更低(14.5 pg/mL vs. 39.4 pg/mL,P=0.04);活化的caspase-1 p35在22例COVID-19患者中检出12例、TBI患者中均未检出,且SOFA评分>9分患者p35灰度分析显著更高。作者认为全身炎症小体活化标志物与预后不直接相关,针对该通路的干预可能效果有限,应以生物标志物为指导。
要点
- 45例重症COVID-19患者入住ICU时院内死亡率为62%。
- COVID-19组半乳糖凝集素-1较TBI组低1.8倍(17101.84 pg/mL vs. 30764.20 pg/mL,P=0.007),其他炎症小体相关标志物浓度相似。
- SOFA评分>9分高死亡风险患者较低风险患者半乳糖凝集素-1更高(25551.3 pg/mL vs. 16302.7 pg/mL,P=0.014)、IL-1RA更低(14.5 pg/mL vs. 39.4 pg/mL,P=0.04)。
- 活化的caspase-1 p35在22例COVID-19患者中检出12例、TBI患者中均未检出,且SOFA评分>9分患者p35灰度分析显著更高。
- 作者认为全身炎症小体活化标志物与预后不直接相关,针对炎症小体通路的干预可能效果有限,应以生物标志物为指导。
适用人群与场景
- 45例重症COVID-19患者和10例无任何感染征象的创伤性脑损伤(TBI)患者,均在入住ICU时采集血浆样本。
诊断标准与关键阈值
- 采用序贯器官衰竭评估(SOFA)评分,以>9分界定高死亡风险患者,较低风险患者为对照。
研究设计与关键结果
- 前瞻性队列研究:纳入45例重症COVID-19患者和10例无感染征象的TBI患者,入住ICU时检测血浆IL-1a、IL-1β、IL-18、IL-1RA、半乳糖凝集素-1、凋亡相关斑点样蛋白、LDH、铁蛋白和gasdermin D,并以基于抑制剂的免疫沉淀后Western Blot进行无细胞caspase-1血浆检测。
- COVID-19患者院内死亡率为62%。
- COVID-19组半乳糖凝集素-1较TBI组低1.8倍(17101.84 pg/mL vs. 30764.20 pg/mL,P=0.007),其他炎症小体相关标志物浓度相似。
- 入住时SOFA评分>9分的高死亡风险患者较低风险患者半乳糖凝集素-1更高(25551.3 pg/mL vs. 16302.7 pg/mL,P=0.014)、IL-1RA更低(14.5 pg/mL vs. 39.4 pg/mL,P=0.04)。
- IL-1a与血小板(r=-0.37)、IL-1β与血小板(r=-0.36)、铁蛋白与INR(r=0.39)呈统计学显著相关。
- 活化的caspase-1 p35在22例COVID-19患者中检出12例、TBI患者中均未检出,其存在与较高纤维蛋白原和较低D-二聚体相关;灰度分析显示SOFA评分>9分患者p35显著更高。
证据类型、等级与局限
- 证据类型:前瞻性队列研究。
- 局限:原文未报告局限性。
对床旁实践的改变
- 作者认为,重症COVID-19患者全身炎症小体活化标志物与预后不直接相关,针对该通路的潜在干预在该组患者中可能效果有限,应以生物标志物为指导。
提炼说明
- 本条依据论文摘要整理;摘要未涉及「处置流程与药物剂量」「红旗征与不能漏的情况」「指南或共识出处」,故未列出这些栏目;全文请点「阅读原文」。
英文原文(摘要)· 点击展开
PURPOSE: The development of targeted biological therapies for coronavirus disease 2019 (COVID-19) requires reliable biomarkers that could help indicate how patients are responding. The hyperactivation of inflammasomes by the SARS-CoV2 virus is hypothesized to contribute to a more severe course of the COVID-19 disease. Therefore, we aimed to evaluate the prognostic value of several inflammasome-related cytokines and proteins upon admission to the intensive care unit (ICU).
PATIENTS AND METHODS: We performed a prospective cohort study. Plasma samples were obtained from 45 critically ill COVID-19 patients and 10 patients without any signs of infection (traumatic brain injury [TBI]) on admission to the ICU. Concentrations of IL-1a, IL-1β, IL-18, IL-1RA, galectin-1, apoptosis-associated speck-like proteins, LDH, ferritin, and gasdermin D were analyzed. A cell-free caspase-1 plasma assay was done by inhibitor-based immunoprecipitation followed by a Western Blot. Demographic and clinical characteristics were recorded.
RESULTS: Inhospital mortality in COVID-19 patients was 62%. Galectin-1 was 1.8-fold lower in COVID-19 than in TBI patients (17101.84 pg/mL vs. 30764.20 pg/mL, P = 0.007), but other inflammasome-related biomarkers had similar concentrations. Patients with a Sequential Organ Failure Assessment (SOFA) score of > 9 on admission who were at high risk of death had significantly higher galectin-1 but lower IL-1RA in comparison with low-risk patients (25551.3 pg/mL vs. 16302.7 pg/mL, P = 0.014; 14.5 pg/mL vs. 39.4pg/mL, P = 0.04, respectively). Statistically significant correlations were observed between: IL-1a and platelets (r = -0.37), IL-1 β and platelets (r = -0.36), ferritin and INR (r = 0.39). Activated caspase-1 p35, whose presence was related to higher fibrinogen and lower D-dimers, was detected in 12 out of 22 COVID-19 patients and in none of the TBI patients. Moreover, densitometric analysis showed a significantly higher amount of p35 in patients with a SOFA score > 9.
CONCLUSION: We found that the systemic markers of activation of inflammasomes in critically ill COVID-19 patients were not directly related to outcome. Therefore, potential interventions aimed at the inflammasome pathway in this group of patients may be of limited effectiveness and should be biomarker-guided.
参考来源
- Adamik B, Ambrożek-Latecka M, Dragan B, et al. Inflammasome-related Markers upon ICU Admission do not Correlate with Outcome in Critically Ill COVID-19 Patients. Shock. 2022. PMID: 35583911. doi:10.1097/SHK.0000000000001923
供执业医师抢救与诊疗参考,不替代临床判断;剂量请结合体重、肝肾功能和本院药品规格复核,以指南原文为准。